Medical expenses in treating acute esophageal variceal bleeding: A 15-year nationwide population-based cohort study. - Wikidata - awgldk - TriplyDB

Medical expenses in treating acute esophageal variceal bleeding: A 15-year nationwide population-based cohort study.

Medical expenses in treating acute esophageal variceal bleeding: A 15-year nationwide population-based cohort study.

http://www.wikidata.org/entity/Q37116892

about

Partial spleen embolization reduces the risk of portal hypertension-induced upper gastrointestinal bleeding in patients not eligible for TIPS implantation

P2860

Q33664268-E92385E8-B2CB-437F-9B04-ABF3C31F28AE

P2860

Medical expenses in treating acute esophageal variceal bleeding: A 15-year nationwide population-based cohort study.

http://www.wikidata.org/entity/Q37116892

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Medical expenses in treating a ...... population-based cohort study.

@en

Medical expenses in treating a ...... population-based cohort study.

@nl

type

label

Medical expenses in treating a ...... population-based cohort study.

@en

Medical expenses in treating a ...... population-based cohort study.

@nl

prefLabel

Medical expenses in treating a ...... population-based cohort study.

@en

Medical expenses in treating a ...... population-based cohort study.

@nl

P1433

Q37116892-1BA9BE26-8A07-48A9-A2D3-74047EA32D2A

P1476

Q37116892-C8C36D77-BB75-4FC6-A0DD-A0C6DF91AFBA

P2093

Q37116892-2E0A932A-9C76-4F77-AB93-F1E807BFDAD9

Q37116892-3B89AAC8-114D-46C2-84C1-AA1FBBA0DF2C

Q37116892-4235151B-00AC-44B3-A5D2-993D5485106E

Q37116892-5EC44506-B658-4DF2-BA5C-0FD145BC19A0

Q37116892-5F7DA547-96DA-4A7D-9939-D9A16CD5F2DF

Q37116892-A9F03992-050C-4561-987A-4AF24C474A5C

Q37116892-B69D4491-8294-4CF4-8F8D-779C1F80B0B9

Q37116892-B98E143E-7B16-4A15-9E7C-8711084CD69F

Q37116892-C7F41D12-B83E-41BF-A227-F81E71C135B3

P2860

Q37116892-01DFF15D-7A81-45D8-8519-3F8AA341B2B8

Q37116892-059E06FF-5060-4932-A68D-FBFEA0470954

Q37116892-06B2F99F-FA5C-474A-B382-2B93ECE8F214

Q37116892-0979B10A-F6B5-48E7-8309-CE755F1FE223

Q37116892-16FC27ED-F257-4CB9-9DA3-AA091A07788E

Q37116892-1C40485F-8FC2-4478-9A34-1A425E0A6535

Q37116892-2D766083-1CC5-4FDD-A0BD-E6FE683D36FE

Q37116892-3A596B10-6E39-4133-8486-C6A5EF950B9C

Q37116892-4D6A85BD-472D-4C28-9CA8-A88F7E666872

Q37116892-596E6250-1507-40DC-A24E-496A7F02C41B

P304

Q37116892-DA0D1086-08DA-4ACF-8044-383CA376C6F3

P31

Q37116892-9BD26978-909B-483B-9BB4-19A9B0CC19E8

P356

Q37116892-C69FCF17-9A27-4E7D-A0B7-3C4E4442D680

P407

Q37116892-7991416F-7D70-4F30-8424-7EE1C5078600

P433

Q37116892-9EBF60F3-180F-4895-8146-7E5BE9DC6FA4

P478

Q37116892-552EADD4-AB60-4A1E-B682-7E8DFE15D45E

P577

Q37116892-EF7A9151-F3E5-4C61-A35B-851C96060B4D

P698

Q37116892-F1D0B157-C163-4443-8398-9A728A04DD9C

P932

Q37116892-AEB08A6C-F459-4F5A-9274-EA4957A1495E

P356

MD.0000000000004215

P1433

P1476

Medical expenses in treating a ...... population-based cohort study.

@en

P2093

Cheng-Kun Wu

http://www.w3.org/2001/XMLSchema#string

Chih-Ming Liang

http://www.w3.org/2001/XMLSchema#string

Chueh-Ling Liu

http://www.w3.org/2001/XMLSchema#string

Hon-Yi Shi

http://www.w3.org/2001/XMLSchema#string

Keng-Liang Wu

http://www.w3.org/2001/XMLSchema#string

Seng-Kee Chuah

http://www.w3.org/2001/XMLSchema#string

Shih-Cheng Yang

http://www.w3.org/2001/XMLSchema#string

Wei-Chen Tai

http://www.w3.org/2001/XMLSchema#string

Yi-Chun Chiu

http://www.w3.org/2001/XMLSchema#string

P2860

Benefits of nucleos(t)ide analog treatments for hepatitis B virus-related cirrhosis

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

Surgeon volume and operative mortality in the United States.

Lamivudine for patients with chronic hepatitis B and advanced liver disease.

The outcome of prophylactic intravenous cefazolin and ceftriaxone in cirrhotic patients at different clinical stages of disease after endoscopic interventions for acute variceal hemorrhage.

U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients.

Declining hospitalization rate of esophageal variceal bleeding in the United States.

The effects of cefazolin on cirrhotic patients with acute variceal hemorrhage after endoscopic interventions.

Comorbidity and survival of Danish cirrhosis patients: a nationwide population-based cohort study.

The effect of systemic antibiotic prophylaxis for cirrhotic patients with peptic ulcer bleeding after endoscopic interventions.

P304

e4215

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MD.0000000000004215

http://www.w3.org/2001/XMLSchema#string

P407

P433

28

http://www.w3.org/2001/XMLSchema#string

P478

95

http://www.w3.org/2001/XMLSchema#string

P577

2016-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27428225

http://www.w3.org/2001/XMLSchema#string

P932

4956819

http://www.w3.org/2001/XMLSchema#string